Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dicloxacillin is a narrow-spectrum beta-lactam antibiotic of the penicillin class, specifically classified as a penicillinase-resistant (beta-lactamase-resistant) penicillin. It is used to treat infections caused by susceptible Gram-positive bacteria, particularly those producing beta-lactamase enzymes such as *Staphylococcus aureus*. Dicloxacillin acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), thereby preventing cross-linking of peptidoglycan chains and leading to cell lysis. It is primarily indicated for mild-to-moderate staphylococcal infections, including skin and soft tissue infections, pneumonia (as adjunct therapy), osteomyelitis, septic arthritis, throat infections due to streptococcus or staphylococcus species, septicaemia, empirical treatment for endocarditis, and surgical prophylaxis[1][2][4][5][6]. Dicloxacillin is available in oral capsule form as dicloxacillin sodium.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dicloxacillin.